Third patient dosed in Initial Dose Cohort in Ph 1 CER-1236 AML Trial
Chris Ehrlich, CERo Therapeutics Chief Executive Officer, stated, “Dosing the third and final planned patient in the starting dose cohort represents an important milestone for CERo. At this lowest dose level, we have observed pharmacokinetic data showing cell expansion, and with IRB approval and customary FDA submission, the protocol has been modified to increase dosing potential within each cohort by allowing for a second infusion in the same subject. While early, these changes are expected to provide valuable information as we prepare to move to higher doses, which are designed to more fully explore the potential for enhanced biological activity. We remain encouraged by the progress of the study and deeply grateful to the patients, investigators, and our team who have made this advancement possible.”
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000